News
Latest Industry Trends
Our three NeoLNP™ transfection kits have just hit the market!
Date:2023-09-25

Lipid nanoparticles (LNP), a type of non-viral vector, are not only crucial tools in life sciences for gene-related research, but also form the foundation for innovative therapies such as RNA therapy and cell therapy. Recently, Scindy Pharmaceutical unveiled a new series of transfection reagent kits, NeoLNP™, which are based on cutting-edge LNP technology. The product range includes an mRNA transfection vector set (for T cells), a siRNA transfection kit (universal), and an mRNA transfection kit (universal).

These kits, representing the next generation of transfection tools, are developed using Scindy Pharmaceutical’s proprietary lipid nanoparticle technology. They utilize innovative, biodegradable, and ionizable lipid materials to achieve siRNA and mRNA encapsulation results comparable to those obtained with professional encapsulation equipment. Importantly, these kits are ethanol-free.

Compared to traditional transfection reagents, these kits offer several benefits, including high efficiency in delivering materials into cells, minimal cell damage, and compatibility with a wide range of cell types. For more information about these products or to place an order, please contact us at service@scindypharm.com. We also invite you to test them with trial applications.


Scindy Pharmaceutical (Suzhou) Co., Ltd.

Address: 6 / F, Block B, Building 4, No. 108 Yuxin Road, Suzhou Industrial Park, Suzhou, Jiangsu, P.R.China

Zip Code: 215125

Tel: +86 (512) 8886-5668

Email: service@scindypharm.com (For Sales)

Email: BD@scindypharm.com (For Cooperation)

【WeChat】
【Official Account】
Copyright © 2023 Scindy Pharmaceutical (Suzhou) Co., Ltd.        ICP NO.: 苏ICP备2021045264号-1